Background: Endothelial dysfunction is the earliest and most important factor in the pathogenesis of atherosclerosis. Inflammation has been shown to contribute to endothelial dysfunction. EECP has been shown to improve endothelial function besides symptomatic benefit in patients with refractory angina. In this patient population, depression has an unfavorable impact on mortality. We evaluated the effect of EECP on endothelial function, inflammatory markers of atherosclerosis and depression.
Results:
The EECP group had a significant improvement in FMD after intervention (14.9+/-3.97, p<0.00018) compared to control group (4.42+/-2.02, p<0.1187). The EECP group also showed a significant increase in the anti-inflammatory marker interleukin-10 (mean 12.06-pre to 22.66-post), but no significant change in other pro-inflammatory markers (ICAM, E-Selectin, IL-6, CRP). EECP treatment showed an improvement in BecksDepression-Scale after treatment (mean 18.13-pre to 10.75-post, p<0.0065).
Conclusion:
EECP group showed a significant improvement in endothelial function compared to the control. There was a significant increase in IL-10, which suggests one or more potential mechanisms of benefit. EECP also showed a significant improvement in symptoms of depression. 
